Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.

O'Reilly, Terence and Mcsheehy, Paul M.J. and Wenger, Fritz and Hattenberger, Marc and Muller, Melanie and Vaxelaire, Juliane and Altmann, Karl-Heinz and Wartmann, Markus (2005) Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. The Prostate, 65 (3). pp. 231-240. ISSN 0270-4137


BACKGROUND: Microtubule agents appear promising for the treatment of prostate cancer. Patupilone (epothilone B), a highly potent non-taxane microtubule stabilizing agent, was evaluated in models of androgen-independent prostate cancer. METHODS: Patupilone was administered to athymic mice bearing human prostate cancer xenografts (subcutaneous DU 145 and PC-3M, orthotopic PC-3M). RESULTS: One 4 mg/kg patupilone administration produced transient regression of DU 145 tumors, while two weekly administrations of 2.5 mg/kg produced stable disease followed by protracted regression, however with more pronounced body weight loss. Taxol (15 mg/kg every other day) weakly inhibited tumor growth, but with less body weight loss. Patupilone (5 mg/kg) produced protracted growth inhibition of subcutaneous PC-3M tumors, with transient body weight loss. In mice with orthotopic PC-3M tumors, 4 or 5 mg/kg/week patupilone impaired primary tumor growth, abrogated metastases and enhanced survival, with only transient body weight loss. CONCLUSIONS: These data suggest that patupilone holds promise for prostate cancer treatment.

Item Type: Article
Related URLs:
Additional Information: archiving not allowed on institutional repository
Keywords: patupilone; epothilones; taxanes; prostate cancer; mouse tumor models
Related URLs:
Date Deposited: 14 Dec 2009 13:57
Last Modified: 31 Jan 2013 01:12


Email Alerts

Register with OAK to receive email alerts for saved searches.